Barclays sets $156 price target for BridgeBio Pharma, which has seen a 28% share price decline since July
BCS Barclays plc ADR
$22.95 0.00%
View chart & analysis → - 1BridgeBio Pharma closed at $65.35 on October 9.
- 2Barclays maintained an Overweight rating for BridgeBio Pharma on October 7 and set a price target of $156.
- 3BridgeBio Pharma recorded $222.4 million in Attruby sales in the U.S. during the second quarter.
So what's the key point?
Barclays set a $156 price target, suggesting BridgeBio Pharma's stock price could rise further. Although the stock price has dropped significantly recently, experts maintain a positive view of the company.
Source TIKR · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.